Semax Research: ACTH-Derived Peptide, Neurobiology and Evidence Limits
The short answer
Semax is a synthetic heptapeptide commonly described by the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It incorporates an ACTH-derived sequence and a Pro-Gly-Pro extension. Research has examined gene expression, neurotrophic signalling, neurotransmission and ischemia-related models.
Most mechanistic evidence is preclinical. Some human studies have been reported, particularly in Russian-language or regional clinical literature, but this does not provide the broad, independently replicated evidence expected for general clinical conclusions.
Structure and research rationale
Semax is derived from an adrenocorticotropic-hormone fragment but is studied as a distinct synthetic peptide. Adding Pro-Gly-Pro changes the molecular material and may influence stability and biological behaviour. Evidence for ACTH, another ACTH fragment or PGP alone cannot automatically be assigned to Semax.
What laboratory studies examine
Cell and animal studies have reported changes in transcripts and proteins associated with immune signalling, neurotrophic pathways, oxidative stress and neurotransmission. Rat focal-ischemia experiments have been used to explore how Semax may alter the response to experimental injury.
Changes in gene or protein expression identify hypotheses and pathways; they do not, by themselves, demonstrate a meaningful organism-level or human outcome.
Animal behavioural findings
Rodent studies have evaluated conditioned responses, learning-related tasks and behaviour after experimental nervous-system injury. Behavioural assays are sensitive to species, model, timing and experimental design. A positive result in a rodent task is not evidence of improved cognition in healthy people.
Human evidence and its limits
Older clinical reports have discussed Semax in acute ischemic-stroke settings and measured neurological or biochemical outcomes. Interpretation is limited by access to complete methods, study size, historical standards, geographic concentration and limited independent replication.
Evidence from a specific clinical preparation and route cannot establish equivalence to separately manufactured research material. It also cannot be generalized to enhancement claims, unrelated populations or routine personal use.
Identity and formulation matter
A Semax label should be supported by material-specific identity evidence. Sequence, terminal form, salt or counter-ion, purity profile, water content and formulation can influence analytical and experimental results. “Semax” is not a substitute for a complete material specification.
Key points
- Semax is an ACTH-derived synthetic heptapeptide.
- Mechanistic research is mainly cellular and animal-based.
- Published human evidence is limited and concentrated.
- Biomarker or expression changes are not clinical outcomes.
- Findings from a pharmaceutical preparation do not establish equivalence to another research material.
What this article does not establish
This article does not establish that Semax improves memory, attention, recovery from neurological injury or any other human outcome. It does not establish that an AURAPEP material is equivalent to a cited preparation, safe, effective or suitable for human use.
References
- Medvedeva EV, et al. Semax regulates expression of immune-response genes after focal cerebral ischemia in rats. Mol Genet Genomics. 2017. https://pubmed.ncbi.nlm.nih.gov/28255762/
- Sudarkina OY, et al. Brain protein expression profile confirms protective effects of Semax in a rat ischemia model. Int J Mol Sci. 2021. https://pubmed.ncbi.nlm.nih.gov/34201112/
- Miasoedova NF, et al. Investigation of mechanisms of the neuroprotective effect of Semax in acute ischemic stroke. 1999. https://pubmed.ncbi.nlm.nih.gov/10358912/
- Dolotov OV, et al. Semax, an analog of ACTH(4-10), and cognitive effects in rats. Neurosci Lett. 2006. https://pubmed.ncbi.nlm.nih.gov/16996037/